A review of tumor markers that are currently used in cancer care.
Introduction
Tumor markers are products that may derive from malignant cells and/or other cells of the organism in response to the onset of cancer [1] [2] [3] [4] [5] . Their production may also be induced by noncancerous benign tumors [1] [2] [3] [4] [5] . Some tumor markers can be detected in malignant tissues obtained from biopsies [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , whereas others can be analyzed in the blood, bone marrow, urine, or other body fluids [20] [21] [22] [23] [24] [25] . Sometimes, tumor markers may also be observed in cancer-free subjects, but in much lower doses than oncological patients. In addition, relatively high levels of a certain tumor marker might develop from various non-malignant pathological conditions, such as liver diseases, inflammations, kidney-related dysfunctions, infections and hematological disorders. On these grounds, high levels of a certain tumor marker in the blood, or in other body fluids might indicate the presence of a malignancy. However, per se, this finding is not sufficient to substantiate the diagnosis of a cancer. For this reason, the analysis of tumor markers in the blood, or other fluids must be combined with the analysis of biopsies, or other tests in order to confirm the diagnosis. The detection of tumor markers can be used for a wide variety of malignancies and for a number of applications, which may comprise diagnosis, follow-up the clinical course of the disease, optimize the efficacy of the treatment, assess the response to therapy and monitor the recurrence of the disease [1] [2] [3] [4] [5] . The National Academy of Clinical Biochemistry and The American Society of Clinical Oncology (ASCO) provide the guidelines for the proper utilization of tumor markers in cancer care, which must be approved by the Food and Drug Administration (FDA), in order to be used in the clinical setting of the United States of America (U.S.A.). This article describes the methods that are adopted for the detection of tumor markers that are currently used in cancer care, along with new strategies that aim at developing personalized medicine programs for the treatment of malignancies. Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1).
Tumor marker Type of tumor/tumors Application
Breast cancer.
To assess the aggressiveness of the malignancy and determine the type of treatment. Table 1 . List of tumor markers that are detected in malignant tissues, other than the blood.
Tumor markers detected in malignant tissues
The detection of these tumor markers requires the removal of a biopsy from the patient [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . In certain cases, biopsy-derived tumor markers are utilized just once, in order to confirm a diagnosis. The list of tumor markers that are analyzed in malignant tissues is summarized in Table 1 .
21-Gene signature (Oncotype DX)
This set of markers is utilized to assess the risk of the reappearance of the tumor in patients with breast cancer [9, [26] [27] [28] . The 21-gene signature comprises genes that are related to the estrogen receptor (ESR1, PGR, BCL2, SCUBE2), HER2 (HER2 and GRB7), cell proliferation (Ki67, STK15, survivin, cyclin B1, MYBL2), cellular invasion (stromelysin3, cathepsin L2), macrophage marker CD68, anti-apoptotic genes (BAG1 and GSTM1) and five housekeeping genes that are used as reference (-actin, GAPDH, RPLPO, GUS and TFRC) [9, [26] [27] [28] . Oncotype DX is a gene-expression profiling that requires RNA samples derived from paraffinembedded tumor biopsies and was introduced for the first time in the U.S.A. market in 2004 (Genomic Health Inc., Redwood City, CA) [29] .
70-Gene signature (MammaPrint)
This set of markers is utilized to assess the risk of the recurrence of the tumor in patients with breast cancer (for a review see references 31-35). In contrast to the 21-Gene signature (Oncotype DX), this assay needs a preparation of fresh tissues in a solution designed to preserve the integrity of RNA molecules [31] . The MammaPrint 70-gene signature test is provided by Agendia Inc. (Irvine, CA).
Anaplastic lymphoma kinase (ALK)
The ALK gene is analyzed for the presence of mutations [33] [34] [35] . This tumor marker may provide useful information both for the prognosis and to determine the type of treatment for non-small cell lung cancer (NSCLC) and anaplastic large cell lymphoma (ALCL) [33] [34] [35] . If mutations are of HER2 expression can be utilized to predict outcomes and to define a line of treatment for breast cancer [13, 14, 69] and advanced stomach cancer [77, 78] . FFPE tumor tissues can be tested for HER2 status either via IHC, or FISH analysis, which utilizes probes contained in the following kits: PathVision (Abbott France SAS, Rungis, France) pharmDx (Dako France SAS, Trappes, France) INFORM (Ventana Medical Systems SA, Ilkirch, France). IHC assays can be carried out either with anti-human HER2 polyclonal antibodies A0485 (Dako France SAS, Trappes, France), or with the HerceoTest kit (Dako France SAS, Trappes, France).
Hormone receptors
All biopsies from patients with breast cancer are tested for estrogen and progesterone receptors [69] . These hormones have the ability to stimulate the proliferation of breast cancer cells [69] . Estrogen receptor expressing breast cancer cells are termed ER-positive, whereas progesterone receptor expressing breast cancer cells are termed PR-positive [69] . Approximately two thirds of breast cancers result positive for at least one of these two hormone receptors [69] . The analysis of hormone receptors in breast cancer cells and in some gynecologic cancers may be utilized for the diagnosis and to determine whether hormone therapy is suitable or not for the treatment of the malignancy [69, [79] [80] [81] [82] [83] [84] . A typical example of hormone therapy is based on tamoxifen [69] . The gynecologic cancers that can be tested for hormone receptors comprise endometrial stromal sarcomas [85, 86] and endometrial cancers [87] [88] [89] . Typically, the ER expression levels in breast cancer tisues can be detected by IHC, with monoclonal antibody ID5 (Dako Cytomation Carpinteria, CA). Another possibile system for monitoring estrogen receptor expression levels is based on PET scan. 18F-fluoroestradiol (18F-FES) is used as a tracer for the PET imaging of ER molecules in breast cancer patients. 18F is generated with a cyclotron (Siemens Eclipse Cyclotron, Siemens Healthcare, Erlangen, Germany; Scanditronix MC-50, Uppsala, Sweden) [85] . 18F-FES synthesis can be conducted as described [85] . Typically, patients receive injections of 222 MBq radiopharmaceutical in 20 ml of isotonic phosphate-buffered saline that contains less than 15% ethanol by volume. The molecular mass and radiochemical and chemical purity of 18F-FES must be evaluated after each synthesis with high-performance liquid chromatography-mass spectrometry analysis (Waters 2690 HPLC, Waters Corporation, Milford, MA; MicroMass ZMD (ES2), Waters Corporation, Milford, MA). Radiochemical purity must be in the range of 98%, whereas the specific activity must be greater than 37 x 1012 Bq/mmol at the time of injection. Patients are positioned supine and imaged with a GE Healthcare Advance PET scanner (Little Chalfont, U.K.). PR expression levels in breast cancer cancer can be assessed by IHC, with monoclonal antibody 636 (Dako Cytomation, Carpinteria, CA). KIT The proto-oncogene KIT is a transmembrane protein, which is also termed CD117 [90] [91] [92] [93] [94] [95] [96] . This proto-oncogene is associated with gastrointestinal stromal tumor [90] [91] [92] and mucosal melanoma [93] [94] [95] [96] . The analysis of this marker is utilized for the diagnosis of the illness and to determine the type of therapeutic intervention in oncological patients with these two types of malignancies [90] [91] [92] [93] [94] [95] [96] . KIT can be detected by IHC in gastrointestinal stromal tumor and mucosal melanoma FFPE tissue sections, by using a rabbit polyclonal antibody against human KIT (Code number A-4502, dilution 1:100; Dako Cytomation, Carpinteria, CA). KRAS Mutations in the KRAS gene may enhance chemo-resistance in advanced colorectal cancer [97, 98] and in certain lung tumors [99] [100] [101] . For instance, cetuximab (or Erbitux) and panitumumab (or Vectibix) are used for the targeting of EGFR in patients with advanced colorectal cancer [102] [103] [104] . However, both cetuximab and panitumumab become essentially useless in patients who carry the mutated KRAS gene and, therefore, these two drugs cannot be administered in therapy. Similarly, KRAS mutations may render some lung cancers more resistant to erlotinib (or Tarceva) and gefitinib (or Iressa) [105] [106] [107] [108] . On these grounds, the analysis of KRAS mutations may provide useful information on the type of treatment that has to be adopted for the treatment of advanced colorectal cancer and certain forms of lung tumors [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] . KRAS gene mutations can be detected with a real-time PCR kit provided by Entrogen, Inc. (Woodland Hills, CA). S-100 S-100 is present in the majority of melanoma cells and may be utilized for the diagnosis of melanoma, following the removal of a biopsy from the patient [17, 18, 109] . This marker can also be detected with blood tests, which allow for the monitoring of the spreading of melanoma before and/or in response to the treatment [110] . S-100 can be detected in FFPE tissue sections with antibodies provided by Dako Cytomation (Carpinteria, CA). Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) These two markers are analyzed to assess the aggressiveness of the malignancy and to determine the type of treatment in patients with breast cancer [8, 111, 112] . An ELISA kit is currently available for the detection of uPA (American Diagnostics, Greenwich, CT). For this protocol, breast tumor biopsies are initially frozen at -70oC. Subsequently, tutmor tissues are homogeneized in 50 mM Tris HCl pH = 7.4, supplemented with 1 mM monothioglycerol (1:7; w/v). The homogenate is then centrifugated at 2,000 g for 10 minutes and the supernatant is extracted with 1% Triton X-100. Another centrifugation step is carried out at 10,000 g for 20 minutes. After this centrifugation, uPA can be detected with the aforementioned ELISA kit. The same protocol for the extraction of uPA can be utilized for PAI-1, which is then detected with another ELISA kit (Monozyme, Horsholm, Denmark). 
Tumor marker

BCR-ABL
This marker is present only in chronic myeloid leukemia (CML) cells and derives from a specific chromosomal translocation, which produces the so-called Philadelphia chromosome [128] [129] [130] [131] [132] [133] [134] . Such a translocation takes place between chromosome 9 and chromosome 22 and is termed t(9;22)(q34;q11). As a consequence, the Abl1 gene on chromosome 9 (region q34) is fused in frame with the BCR (breakpoint cluster region) gene on chromosome 22 (region q11). The resulting fusion gene is termed BCR-ABL, which is tested either in the blood, or in the bone marrow via polymerase chain reaction (PCR). In addition to the diagnosis of CML, BCR-ABL may be used to follow the response to therapy and can be analyzed with a real time PCR kit (QuantidexTM BCR-ABL IS CMR Kit; Asuragen, Austin, TX) [128- 164, 166, 191] . High CA 27-29 levels may also be present in patients with cancers of the uterus, ovary, kidney, liver, pancreas, stomach, colon and lung [192] . CA 27-29 is an additional marker utilized for the diagnosis and follow-up the clinical course of breast cancer before and/or after the therapy. However, not all the patients with breast cancer exhibit high levels of CA 27-29 [162, [193] [194] [195] . In addition, considerable CA 27-29 levels may be present in subjects who do not have cancer, such as women in the first trimester of pregnancy [196] , or with noncancerous breast disease [197] . CA 27-29 may also be associated with ovarian cysts [198] This marker may be utilized for the prognosis, to follow-up the response to therapy and to monitor the recurrence of the tumor. However, high LDH levels may also be detected in noncancerous conditions, such as liver disease, hematological illnesses, muscle injury, heart attack and stroke [293] . For this reason LDH is less useful for the diagnosis of the aforementioned malignancies than the markers AFP and HCG [293] . An Elisa kit is available for the detection of LDH (abcam; Cambridge, MA).
Neuron-specific enolase (NSE)
NSE is detected in the blood of patients with neuroendocrine tumors, such as neuroblastoma [294] [295] [296] , carcinoid tumors [296] [297] [298] [299] and small cell lung cancer [292, 295] . This marker is utilized for the follow-up of the response to therapy. High levels of this marker are also present in melanoma [294] , pancreatic endocrine tumors [300, 301] and medullary thyroid cancer [302, 303] . NSE can be readily detected with an Elisa kit (Alpha Diagnostic Intl., Inc.; San Antonio, TX).
Nuclear Matrix protein 22 (NMP22)
This marker is detected in the urine of patients with bladder cancer and is utilized for the diagnosis of the disease [304] [305] [306] . NMP22 may be present in the urine of patients who had a recent chemotherapeutic intervention, or underwent intravesical immunotherapy [307, 308] . An Elisa kit can be utilized for the detection of NMP22 (MyBioSource, Inc.; San Diego, CA). Prostate-specific antigen (PSA) PSA is detected in the blood of patients with prostate cancer and is utilized for the diagnosis, to follow-up the response to therapy and to monitor the clinical course of the disease [309] [310] [311] . This marker is also present in noncancerous conditions, such as benign prostatic hyperplasia (BPH 
